Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel

Chemotherapy

Volumn 51, Issue 6, 2005, Pages 311-318

  Lee, Seung Ju ^a   Sae, Woong Kim ^a,c   Chung, Hesson ^b   Yeong, Taek Park ^b   Young, Wook Choi ^b   Cho, Yong Hyun ^a   Moon, Soo Yoon ^a  

^a The Catholic University of Korea   (South Korea)

^b Chung Ang University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Absorption; Bladder cancer; Drug delivery systems; Intravesical administration; Paclitaxel; Toxicity

Indexed keywords

GLYCEROL OLEATE; PACLITAXEL; WATER;

ADHESION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BLADDER CARCINOMA; BLADDER SURGERY; CANCER CHEMOTHERAPY; CAPILLARY; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG INSTILLATION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; EXCISION; FEMALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; TIME; TISSUE PERFUSION; TOXICITY; UROTHELIUM;

ABSORPTION; ADMINISTRATION, INTRAVESICAL; ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DELIVERY SYSTEMS; FEMALE; GLYCERIDES; PACLITAXEL; RABBITS; URINARY BLADDER NEOPLASMS;

EID: 27544465849     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088953     Document Type: Article

References (19)

1. Duque JL, Loughlin KR: An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000;27:125-135.
2. Herr HW, Laudone VP, Whitmore WF Jr: An overview of intravesical therapy for superficial bladder tumors. J Urol 1987;138:1363-1368.
3. Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183.
4. Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF Jr: Superficial bladder cancer treated with Bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol 1989;141:22-29.
5. Rowinsky EK, Donehower RC, Jones RJ, Tucker RW: Microtubule changes and cytotoxicity in leukemic cell line treated with taxol. Cancer Res 1988;48:4093-4100.
6. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ: Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-2270.
7. Dreicer R, Gustin DM, See WA, Williams RD: Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. J Urol 1996;156:1606-1608.
8. Knemeyer I, Wientjes MG, Au JL: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 1999;44:241-248.
9. Engstrom S: Drug delivery from cubic and other lipid-water phases. Lipid Technol 1990;2:42-45.
10. Engstrom S, Engstrom L: Phase behavior of the lidocaine-monoolein-water system. Int J Pharm 1992;79:113-122.
11. Longer M, Tyle P, Mauger J: A cubic-phase oral drug delivery system for controlled release of AG337. Drug Dev Ind Pharm 1996;7:603-608.
12. Song D, Au JL: Isocratic high-performance liquid chromatographic assay of Taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Appl 1995;633:337-344.
13. Wientjes MG, Badalament RA, Au JL: Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32:255-262.
14. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL: Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991;51:4347-4354.
15. Wientjes MG, Badalament RA, Au JL: Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 1996;37:539-546.
16. Rangel C, Niell H, Miller A, Cox C: Taxol and taxotere in bladder cancer: In vitro activity and urine stability. Cancer Chemother Pharmacol 1994;33:460-464.
17. Turnbull GJ: Ultrastructural basis of the permeability barrier in urothelium. Invest Urol 1973;11:198-204.
18. Hyde ST, Ericsson B, Anderson S, Larsson K: A cubic structure consisting of a lipid bilayer forming an infinite periodic minimum surface of the gyroid type in the glycerylmonooleate-water system. Z Kristallogr 1984;168:213-219.
19. Nielsen LS, Schubert L, Hansen J: Bioadhesive drug delivery systems. I. Characterisation of mucoadhesive properties of systems based on glyceryl mono-oleate and glyceryl monolinoleate. Eur J Pharm Sci 1998;6:231-239.